Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias

NCT01154816 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01154816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01154816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
June 30, 2019
Enrollment
118 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

hepatoblastoma, previously treated childhood rhabdomyosarcoma, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent childhood kidney neoplasm, recurrent childhood malignant germ cell tumor, recurrent childhood rhabdomyosarcoma, recurrent childhood soft tissue sarcoma, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent neuroblastoma, recurrent osteosarcoma